Researchers have identified specific genetic changes that can result in newborns having little to no immune protection against illness.

Researchers from Newcastle University, the Wellcome Sanger Institute, the Great North Children's Hospital, and their collaborators were able to connect mutations in the NUDCD3 gene to rare and potentially fatal immunodeficiency disorders called Omenn syndrome1 and Severe Combined Immunodeficiency in a recent study involving 11 affected individuals.

The normal development of the variety of immune cells required to fight various infections was impeded by these mutations2.

The results, which were released in Science Immunology, present potential for this condition's early detection and treatment.

Severe Combined Immunodeficiency (SCID) and Omenn syndrome are both rare genetic disorders that leave children without a functional immune system and at risk of life-threatening infections.

Without urgent treatment, such as stem cell transplants to replace the faulty immune system, many affected will not survive their first year.

While newborn screening methods can flag T cell deficiency, knowledge of the specific genetic cause increases confidence in the diagnosis of SCID and informs the choice of curative therapy. Currently, this remains out of reach for at least 1 in 10 affected families.

In this new study, researchers from Newcastle University, the Wellcome Sanger Institute and their collaborators studied 11 children across four families, two of whom had SCID while the other nine had Omenn syndrome.

All had inherited mutations that disrupted the function of the NUDCD3 protein, which had not previously been linked to the immune system.

Using detailed studies of patient-derived cells and the experimental models, the team demonstrated that NUDCD3 mutations impair a crucial gene-rearranging process called V(D)J recombination, essential for generating the diverse T cell receptors and antibodies needed to recognise and fight different pathogens.

While the experimental model engineered with the same NUDCD3 mutations had milder immune problems, the human patients faced severe, life-threatening consequences.

Two patients did survive, however, after receiving a stem cell transplant - reinforcing the importance of early diagnosis and intervention.

Dr Gosia Trynka, author of the study at the Wellcome Sanger Institute and science director at Open Targets, said: "For babies born with high-risk immunodeficiencies, early detection can mean the difference between life and death. These diseases leave newborns essentially defenceless against pathogens that most of us can easily fend off. The identification of this new disease gene will help clinicians to make a prompt molecular diagnosis in affected patients, meaning they can receive life-saving treatments more quickly."

Professor Sophie Hambleton, senior author of the study at Newcastle University and practising paediatric immunologist at the Great North Children's Hospital, said:

"SCID and Omenn syndrome are devastating disorders, requiring complex and timely treatments. The more we can understand its underlying causes, the better we can look after affected babies. Our research is aimed at filling in the gaps so that families can achieve a molecular diagnosis while we continue learning more about how the immune system works in health and disease. We are deeply grateful to the families whose invaluable participation in this study will help future generations."